Working… Menu
Trial record 62 of 2813 for:    Neoplasms | Neuroendocrine Tumors

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03420521
Recruitment Status : Recruiting
First Posted : February 2, 2018
Last Update Posted : September 23, 2019
Bristol-Myers Squibb
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 15, 2023
Estimated Study Completion Date : January 15, 2024